TY - JOUR AU - Cheriyan, Salim K. AU - Nicholson, Marilin AU - Aydin, Ahmet M. AU - Azizi, Mounsif AU - Peyton, Charles C. AU - Sexton, Wade J. AU - Gilbert, Scott M. PY - 2019 TI - Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors JF - Translational Andrology and Urology; Vol 9, Supplement 1 (January 11, 2020): Translational Andrology and Urology (Testicular Cancer) Y2 - 2019 KW - N2 - Early stage nonseminomatous germ cell tumor (NSGCT) remains a treatable disease, with stage I cancer specific survival exceeding 95%. Using a risk-adapted approach; active surveillance (AS), adjuvant chemotherapy, and retroperitoneal lymph node dissection (RPLND) all options for treatment; with surveillance being increasingly used. With persistently elevated markers (stage IS), chemotherapy remains the hallmark of treatment. Management of stage II NSGCT varies based on status of tumor markers. With negative markers, both induction chemotherapy and upfront RPLND remain options. Management of a residual mass <1 cm after chemotherapy remains controversial, with AS and nerve-sparing RPLND considered options. The development of miR-371a-3p microRNA shows promise a novel biomarker for testicular cancer (GCT). Despite controversies in management, cures for NSGCT are achievable in 95–99% of patients. UR - https://tau.amegroups.org/article/view/26603